Frazier Life Sciences Management, L.P. — 13F Holdings & Portfolio
CIK 1892134 · latest 13F-HR filed 2026-08-14
Frazier Life Sciences Management, L.P. manages $4.59B in 13F-reported U.S. long-equity assets across 41 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are MIRM (19.58%), NAMS (13.35%), ERAS (9.96%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 6 new positions and exited 3; 27 existing positions rose in reported value and 5 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 73.6%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 31, 2026.
BUILDING 4, SUITE 200B
PALO ALTO, CA 94304
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| BRUSH, JAMES Control | GENERAL PARTNER & PORTFOLIO MANAGER since Nov 2021 | Less than 5% | Individual |
| CHA, ALBERT, (NMN) Control | MANAGING PARTNER since Nov 2021 | Less than 5% | Individual |
| EMPEY, GORDON Control | CHIEF OPERATING OFFICER since Mar 2025 | Less than 5% | Individual |
| ESTES, DANIEL Control | GENERAL PARTNER since Nov 2021 | Less than 5% | Individual |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.L.C. Control | GENERAL PARTNER since Nov 2021 | Less than 5% | Domestic Entity |
| GALENA HOLDINGS INC Control | LIMITED PARTNER since Nov 2021 | 50–75% | Domestic Entity |
| HERON, PATRICK, JAMES Control | MANAGING PARTNER since Nov 2021 | Less than 5% | Individual |
| MARTIN, JENNIFER, J Control | CHIEF FINANCIAL OFFICER since Jan 2026 | Less than 5% | Individual |
| TOPPER FAMILY INC Control | LIMITED PARTNER since Nov 2021 | 50–75% | Domestic Entity |
| TOPPER, JAMES, NEWMAN Control | MANAGING PARTNER since Nov 2021 | Less than 5% | Individual |
| ONTIVEROS, DANIEL, M | CHIEF COMPLIANCE OFFICER since Jan 2026 | Less than 5% | Individual |
| HERON, PATRICK, JAMES Control Indirect owner via GALENA HOLDINGS INC | MEMBER since Jan 2021 | 75% or more | Individual |
| TOPPER, JAMES, NEWMAN Control Indirect owner via TOPPER FAMILY INC | MEMBER since Jan 2021 | 75% or more | Individual |
Ownership & leadership changes · 2 filings with changes since Nov 18, 2021
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- No longer listedBAILEY, STEVE, RAY · CHIEF FINANCIAL OFFICER & CHIEF COMPLIANCE OFFICER · Less than 5% · control person · listed since Nov 2021
- AddedMARTIN, JENNIFER, J · CHIEF FINANCIAL OFFICER · Less than 5% · control person
- AddedONTIVEROS, DANIEL, M · CHIEF COMPLIANCE OFFICER · Less than 5%
- No longer listedGALENA HOLDINGS, LLC · LIMITED PARTNER · 50–75% · control person · listed since Nov 2021
- No longer listedHERON, PATRICK, JAMES · MEMBER · 75% or more · indirect via GALENA HOLDINGS, LLC · control person · listed since Jan 2021
- No longer listedTOPPER FAMILY, LLC · LIMITED PARTNER · 50–75% · control person · listed since Nov 2021
- No longer listedTOPPER, JAMES, NEWMAN · MEMBER · 75% or more · indirect via TOPPER FAMILY, LLC · control person · listed since Jan 2021
- AddedEMPEY, GORDON · CHIEF OPERATING OFFICER · Less than 5% · control person
- AddedGALENA HOLDINGS INC · LIMITED PARTNER · 50–75% · control person
- AddedHERON, PATRICK, JAMES · MEMBER · 75% or more · indirect via GALENA HOLDINGS INC · control person
- AddedTOPPER FAMILY INC · LIMITED PARTNER · 50–75% · control person
- AddedTOPPER, JAMES, NEWMAN · MEMBER · 75% or more · indirect via TOPPER FAMILY INC · control person
- ListedBAILEY, STEVE, RAY · CHIEF FINANCIAL OFFICER & CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ListedBRUSH, JAMES · GENERAL PARTNER & PORTFOLIO MANAGER · Less than 5% · control person
- ListedCHA, ALBERT, (NMN) · MANAGING PARTNER · Less than 5% · control person
- ListedESTES, DANIEL · GENERAL PARTNER · Less than 5% · control person
- ListedFRAZIER LIFE SCIENCES MANAGEMENT, L.L.C. · GENERAL PARTNER · Less than 5% · control person
- ListedGALENA HOLDINGS, LLC · LIMITED PARTNER · 50–75% · control person
- ListedHERON, PATRICK, JAMES · MANAGING PARTNER · Less than 5% · control person
- ListedHERON, PATRICK, JAMES · MEMBER · 75% or more · indirect via GALENA HOLDINGS, LLC · control person
- ListedTOPPER FAMILY, LLC · LIMITED PARTNER · 50–75% · control person
- ListedTOPPER, JAMES, NEWMAN · MANAGING PARTNER · Less than 5% · control person
- ListedTOPPER, JAMES, NEWMAN · MEMBER · 75% or more · indirect via TOPPER FAMILY, LLC · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- MIRUM PHARMACEUTICALS INC$189.6M +26.7%
- MBX BIOSCIENCES INC$168.6M +84.9%
- NEWAMSTERDAM PHARMA COMPANY$70.7M +13.0%
- TREVI THERAPEUTICS INC$66.8M +56.3%
- ERASCA INC$58.3M +14.6%
Top Trims
- BRIDGEBIO PHARMA INC-$140.8M -55.0%
- TARSUS PHARMACEUTICALS INC-$5.3M -10.3%
- LEXEO THERAPEUTICS INC-$2.9M -11.6%
- VALNEVA SE-$2.3M -16.3%
- IBIO INC-$293.0K -7.9%
New Positions
- PARABILIS MEDICINES INC$52.6M
- ACHIEVE LIFE SCIENCE INC$49.7M
- DESIGN THERAPEUTICS INC$26.2M
- SHATTUCK LABS INC$26.0M
- KAILERA THERAPEUTICS INC$24.2M
Exited Positions
Show all 3 →Frazier Life Sciences Management, L.P. Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | MIRUM PHARMACEUTICALS INC | MIRM | 604749101 | $899.1M | 19.58% | 7,679,684 | SH |
| 2 | NEWAMSTERDAM PHARMA COMPANY | NAMS | N62509109 | $613.0M | 13.35% | 18,088,902 | SH |
| 3 | ERASCA INC | ERAS | 29479A108 | $457.5M | 9.96% | 24,975,188 | SH |
| 4 | MBX BIOSCIENCES INC | MBX | 55287L101 | $367.2M | 8.00% | 6,652,013 | SH |
| 5 | ARCUTIS BIOTHERAPEUTICS INC | ARQT | 03969K108 | $258.9M | 5.64% | 9,874,511 | SH |
| 6 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $185.4M | 4.04% | 9,939,447 | SH |
| 7 | KRYSTAL BIOTECH INC | KRYS | 501147102 | $178.9M | 3.90% | 481,307 | SH |
| 8 | MAZE THERAPEUTICS INC | MAZE | 578784100 | $150.2M | 3.27% | 5,032,915 | SH |
| 9 | PHATHOM PHARMACEUTICALS INC | PHAT | 71722W107 | $135.3M | 2.95% | 12,466,489 | SH |
| 10 | PALVELLA THERAPEUTICS INC NE | PVLA | 697947109 | $134.8M | 2.94% | 882,400 | SH |
| 11 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $115.3M | 2.51% | 1,548,139 | SH |
| 12 | DISC MEDICINE INC | IRON | 254604101 | $99.1M | 2.16% | 1,354,852 | SH |
| 13 | CYTOKINETICS INC | CYTK | 23282W605 | $98.8M | 2.15% | 1,159,879 | SH |
| 14 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $70.0M | 1.53% | 3,153,082 | SH |
| 15 | ASCENDIS PHARMA A/S | ASND | 04351P101 | $60.1M | 1.31% | 225,155 | SH |
| 16 | SAVARA INC | SVRA | 805111101 | $59.9M | 1.30% | 9,720,852 | SH |
| 17 | PARABILIS MEDICINES INC | PBLS | 698955101 | $52.6M | 1.14% | 1,920,805 | SH |
| 18 | AURA BIOSCIENCES INC | AURA | 05153U107 | $50.4M | 1.10% | 7,100,000 | SH |
| 19 | ACHIEVE LIFE SCIENCE INC | QUIT | 004468500 | $49.7M | 1.08% | 7,614,836 | SH |
| 20 | VOR BIOPHARMA INC | VOR | 929033207 | $46.8M | 1.02% | 2,543,939 | SH |
| 21 | ALLOGENE THERAPEUTICS INC | ALLO | 019770106 | $46.7M | 1.02% | 22,446,668 | SH |
| 22 | TARSUS PHARMACEUTICALS INC | TARS | 87650L103 | $45.9M | 1.00% | 728,644 | SH |
| 23 | BIOCRYST PHARMACEUTICALS INC | BCRX | 09058V103 | $40.1M | 0.87% | 4,009,240 | SH |
| 24 | ALKERMES PLC | ALKS | G01767105 | $36.7M | 0.80% | 700,647 | SH |
| 25 | ACADIA PHARMACEUTICALS INC | ACAD | 004225108 | $36.4M | 0.79% | 1,438,198 | SH |
| 26 | ZAI LAB LTD | ZLAB | 98887Q104 | $36.1M | 0.79% | 1,902,320 | SH |
| 27 | MANNKIND CORP | MNKD | 56400P706 | $28.1M | 0.61% | 6,600,000 | SH |
| 28 | DESIGN THERAPEUTICS INC | DSGN | 25056L103 | $26.2M | 0.57% | 1,809,854 | SH |
| 29 | ACLARIS THERAPEUTICS INC | ACRS | 00461U105 | $26.1M | 0.57% | 4,925,374 | SH |
| 30 | SHATTUCK LABS INC | STTK | 82024L103 | $26.0M | 0.57% | 3,750,000 | SH |
| 31 | KAILERA THERAPEUTICS INC | KLRA | 482931102 | $24.2M | 0.53% | 1,100,000 | SH |
| 32 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $24.2M | 0.53% | 1,000,000 | SH |
| 33 | LEXEO THERAPEUTICS INC | LXEO | 52886X107 | $22.5M | 0.49% | 4,824,725 | SH |
| 34 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $19.0M | 0.41% | 1,015,693 | SH |
| 35 | EVOLUS INC | EOLS | 30052C107 | $18.3M | 0.40% | 2,630,665 | SH |
| 36 | IMMUNOCORE HLDGS PLC | IMCR | 45258D105 | $15.4M | 0.34% | 484,782 | SH |
| 37 | VALNEVA SE | VALN | 92025Y103 | $12.0M | 0.26% | 2,291,666 | SH |
| 38 | NEWAMSTERDAM PHARMA COMPANY | NAMSW | N62509117 | $10.7M | 0.23% | 500,333 | SH |
| 39 | AUTOLUS THERAPEUTICS LTD | AUTL | 05280R100 | $7.1M | 0.15% | 4,447,910 | SH |
| 40 | XILIO THERAPEUTICS INC | XLO | 98422T209 | $4.0M | 0.09% | 422,505 | SH |
| 41 | IBIO INC | IBIO | 451033708 | $3.4M | 0.07% | 1,953,467 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $4.59B | 41 | 0001892134-26-000003 |
| 2026-03-31 | 2026-05-15 | $3.89B | 38 | 0001892134-26-000002 |
| 2025-12-31 | 2026-02-13 | $3.72B | 40 | 0001892134-26-000001 |
| 2025-09-30 | 2025-11-14 | $3.34B | 47 | 0001892134-25-000012 |
BUILDING 4, SUITE 200B
PALO ALTO, CA 94304